Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,620
  • Shares Outstanding, K 11,780
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,400 K
  • 36-Month Beta -7.45
  • Price/Sales 278,867.32
  • Price/Cash Flow N/A
  • Price/Book 1.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +1,110,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +13.51%
on 09/04/18
2.36 -11.02%
on 09/04/18
+0.21 (+11.11%)
since 08/21/18
3-Month
1.81 +16.02%
on 08/09/18
2.46 -14.63%
on 06/25/18
+0.10 (+5.00%)
since 06/21/18
52-Week
1.70 +23.53%
on 03/28/18
10.49 -79.98%
on 09/22/17
-6.64 (-75.97%)
since 09/21/17

Most Recent Stories

More News
Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin's bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways

-- Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model

AKTX : 2.10 (+0.48%)
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation (NYSE:BRC),...

AKTX : 2.10 (+0.48%)
SRNE : 4.18 (-6.07%)
MTGE : 19.80 (-0.25%)
BRC : 44.65 (-0.45%)
NEWR : 97.85 (-0.21%)
JLL : 144.82 (-0.81%)
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX

The Rosen Law Firm, P.A. announces that the United States District Court Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers...

AKTX : 2.10 (+0.48%)
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials

-- Trials in which complement dysregulation is the primary disease driver -- CAPSTONE, the Phase III trial in naive paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced

AKTX : 2.10 (+0.48%)
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today...

AKTX : 2.10 (+0.48%)
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases

Stock Monitor: Akari Therapeutics Post Earnings Reporting

AKTX : 2.10 (+0.48%)
TTPH : 3.03 (-4.11%)
Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc....

NEWT : 21.78 (-0.50%)
AKTX : 2.10 (+0.48%)
CACC : 447.80 (+0.86%)
BRC : 44.65 (-0.45%)
CHIAV : 13.53 (+12.75%)
CHUBA : 22.73 (+0.04%)
FSCT : 40.04 (+1.44%)
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress

-- Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naive Trial

AKTX : 2.10 (+0.48%)
Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today...

AKTX : 2.10 (+0.48%)
Key FDA Approvals Paramount Catalyst for Biotech Run Heading Into November

The FDA has approved 34 drugs to date in 2017 after approving 22 novel drugs last year. Many biotech and pharma companies have dealt with the drug development process being lengthy and time-consuming along...

AKTX : 2.10 (+0.48%)
CTXR : 1.52 (-4.40%)
ADMS : 19.38 (-1.52%)
ECYT : 17.74 (+0.62%)
MNKD : 1.66 (-1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade AKTX with:

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

2nd Resistance Point 2.19
1st Resistance Point 2.14
Last Price 2.10
1st Support Level 1.99
2nd Support Level 1.89

See More

52-Week High 10.49
Fibonacci 61.8% 7.13
Fibonacci 50% 6.09
Fibonacci 38.2% 5.06
Last Price 2.10
52-Week Low 1.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar